Autopsy report · NCT02353572
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Cause of deathStaffing, sites or logistics
“Principle investigator left the institution”
Life of this trial
- Registered 5 years 2 months after it had already started.
- Ran for about 1 year 10 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 3 years 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Conditions
- Plasma Cell Myeloma; Plasmacytosis; Recurrent Plasma Cell Myeloma; Smoldering Plasma Cell Myeloma
- Interventions
- Melphalan; Bortezomib; Dexamethasone; Autologous Transplant
- Participants
- 3
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Intralesional Tetracycline Injection in the Treatment of Chalazia
“Investigator left the institution” - TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory
“The study principle investigator left the institution.” - Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
“the Principal Investigator left the institution” - Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study
“Principal Investigator left the institution” - Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
“Investigator left institution”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.